Statistical analysis
death
REGRESSION
PFS and OS in all evaluable patients were calculated using Kaplan-Meier curves. PFS was the interval to progression or death in those evaluable for efficacy. Duration of treatment was defined as the date from first dose of IFN-γ to progression, death, or completion of all treatments. The ORR was calculated using RECIST v 1.1. Planned exploratory correlative analysis of the difference in immune parameters at various treatment time points was done using a Wilcoxon test where consecutive samples from the same patient constituted a pair. Correlations to duration of treatment were performed using a Cox proportional hazards regression and tests for dose dependence were done using a Kruskal–Wallis test. For the post-hoc cytokine analysis, a two-sided Wilcoxon test was used to compare cytokine levels and in order to account for multiple hypotheses, the Benjamini–Hochberg false discovery rate (FDR) was computed, separately, for each comparison performed (baseline vs. C1D1, baseline vsC1D15, C1D1 vs C1D15). Cytokines with FDR corrected 